Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


GUIDELINE TITLE

Age-related macular degeneration. Limited revision.

BIBLIOGRAPHIC SOURCE(S)

  • American Academy of Ophthalmology (AAO). Age-related macular degenration. Preferred practice pattern. San Francisco (CA): American Academy of Ophthalmology (AAO); 2006. 33 p. [134 references]

REFERENCES SUPPORTING THE RECOMMENDATIONS

  • Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001 Oct;119(10):1417-36. PubMed


  • Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991 Aug;109(8):1109-14. PubMed


  • Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006 Mar;113(3):363-372.e5. PubMed


  • Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P, Schachat AP, Strong HA, Wenkenstern A. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol 2003 Sep;121(9):1253-68. PubMed


  • Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006 Jul;142(1):1-9. PubMed


  • Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001 Feb;119(2):198-207. PubMed


  • Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Macular Photocoagulation Study Group. Arch Ophthalmol 1993 Sep;111(9):1189-99. PubMed


  • Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 Dec 30;351(27):2805-16. PubMed


  • Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, Bird AC, Genetic Factors in AMD Study. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006 Jan;90(1):75-80. PubMed


  • Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997 Jan;104(1):7-21. PubMed


  • Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1994 Apr;112(4):500-9. PubMed


  • Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006 Mar;26(3):270-4. PubMed


  • National Cancer Institute. Tobacco and the clinician: interventions for medical and dental practice [NIH Publication No. 94-3693]. Bethesda (MD): National Cancer Institute; 1994. 1-12 p. (Monograph; no. 5).


  • Ockene JK. Smoking intervention: the expanding role of the physician. Am J Public Health 1987 Jul;77(7):782-3. PubMed


  • Ophthalmic Mutual Insurance Company. Informed consent form for Avastin (Bevacizumab) intravitreal injection. San Francisco (CA): Ophthalmic Mutual Insurance Company (OMIC); 2006.


  • Pederson LL, Baskerville JC, Wanklin JM. Multivariate statistical models for predicting change in smoking behavior following physician advice to quit smoking. Prev Med 1982 Sep;11(5):536-49. PubMed


  • Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy(TAP). Arch Ophthalmol 1999 Oct;117(10):1329-45. PubMed


  • Preferred Practice Patterns Committee. Comprehensive adult medical eye evaluation. San Francisco (CA): American Academy of Ophthalmology (AAO); 2005. 15 p.  (Preferred practice pattern). [76 references]


  • Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006 May-Jun;26(5):495-511. PubMed


  • Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol 2006 Jul;124(7):995-1001. PubMed


  • Smiddy WE, Fine SL. Prognosis of patients with bilateral macular drusen. Ophthalmology 1984 Mar;91(3):271-7. PubMed


  • Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006 Apr;26(4):383-90. PubMed


  • Strahlman ER, Fine SL, Hillis A. The second eye of patients with senile macular degeneration. Arch Ophthalmol 1983 Aug;101(8):1191-3. PubMed


  • Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye 2005 Sep;19(9):935-44. [55 references] PubMed


  • U.S. Food and Drug Administration. Labeling instructions for Pegaptanib , (NDA) 021756. Rockville (MD): U.S. Food and Drug Administration; 2006.


  • U.S. Food and Drug Administration. Labeling instructions for Ranibizumab, (BLA) 125156. Rockville (MD): U.S. Food and Drug Administration; 2006.


  • Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including: lesions with occult with no classic choroidal neovascularization -- verteporfin in photodyna. Am J Ophthalmol 2001 May;131(5):541-60. PubMed


© 1998-2009 National Guideline Clearinghouse

Date Modified: 2/9/2009

 

 

   
DHHS Logo